Lapix Therapeutics

Lapix Therapeutics Inc.

25 Investors

Biopharmaceuticals

BOSTON, MA

Lapix Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Cambridge, MA, dedicated to developing innovative oral therapeutics that restore immune system function for patients with autoimmune diseases. Through a patient-centric approach, Lapix Therapeutics is pioneering treatments that enhance the body's natural immune tolerance.

Products & Team

LPX-TI641

Immune restoration drugSeed

LPX-TI641 is an oral small-molecule drug developed to target the T cell/transmembrane, immunoglobulin, and mucin (Tim) family of receptors. It is designed to restore the body’s natural immune tolerance in patients with autoimmune diseases.

Value Proposition

LPX-TI641 addresses autoimmune diseases by providing a safe approach to restore immune balance without the severe side effects of existing treatments.

Pain Points

Current treatments often suppress the whole immune system, leading to serious side effects and increased vulnerability to infections.

Targets Tim family of receptorsRestores immune toleranceOral administrationPromising safety profileAvoids neutropenia and lymphocytopenia